(Q37981884)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22310849%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

title

SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22310849%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

language of work or name

1 reference

7 February 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22310849%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Endocrinology

22 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22310849%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22310849%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22310849%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

page(s)

495-502

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22310849%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrendo.2011.243

22 January 2020

exact match

0 references

cites work

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

Diminished glucagon suppression after β-cell reduction is due to impaired α-cell function rather than an expansion of α-cell mass

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

The stunned beta cell: a brief history

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

Targeting type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

Type 2 diabetes as an inflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

Role of reactive oxygen species in the progression of type 2 diabetes and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

Glucose regulation of islet stress responses and beta-cell failure in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

Glucose regulation of β-cell stress in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

Biology of human sodium glucose transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

Glucose transport by human renal Na+/D-glucose cotransporters SGLT1 and SGLT2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

SGLT1, a novel cardiac glucose transporter, mediates increased glucose uptake in PRKAG2 cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

High glucose levels down-regulate glucose transporter expression that correlates with increased oxidative stress in placental trophoblast cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

Glucose-transporter-mediated positive inotropic effects in human myocardium of diabetic and nondiabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

Glucose transporters in the transepithelial transport of glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

SGLT2 mediates glucose reabsorption in the early proximal tubule.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

Active sugar transport in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

Familial renal glycosuria: a genetic reappraisal of hexose transport by kidney and intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

Pharmacodynamic model of sodium-glucose transporter 2 (SGLT2) inhibition: implications for quantitative translational pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

HNF1alpha controls renal glucose reabsorption in mouse and man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

Mutations in the hepatocyte nuclear factor-1alpha gene in maturity-onset diabetes of the young (MODY3)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

Angiotensin II-dependent increased expression of Na+-glucose cotransporter in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

The Sweet Pee model for Sglt2 mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

Molecular basis for glucose-galactose malabsorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

Novel compound heterozygous mutations in SLC5A2 are responsible for autosomal recessive renal glucosuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

Twenty-one additional cases of familial renal glucosuria: absence of genetic heterogeneity, high prevalence of private mutations and further evidence of volume depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

Familial renal glucosuria: SLC5A2 mutation analysis and evidence of salt-wasting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

Aglycone exploration of C-arylglucoside inhibitors of renal sodium-dependent glucose transporter SGLT2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

Multiple-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy overweight and obese subjects: a randomized double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

HbA₁(c) and mean blood glucose show stronger associations with cardiovascular disease risk factors than do postprandial glycaemia or glucose variability in persons with diabetes: the A1C-Derived Average Glucose (ADAG) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

SGLT2 inhibitors: molecular design and potential differences in effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

Discovery of novel N-β-D-xylosylindole derivatives as sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the management of hyperglycemia in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

Emerging treatment options for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

Renal hemodynamics and segmental tubular reabsorption in early type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

Facilitative glucose transporter 9, a unique hexose and urate transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

Neuronal regulation of homeostasis by nutrient sensing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

Functional expression of SGLTs in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

Renal threshold for glucose in non-insulin-dependent diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

Maximum Tubular Reabsorption Capacity for Glucose and Renal Hemodynamics during Rapid Hypertonic Glucose Infusion in Normal and Diabetic Subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

Regulation of renal glucose transporters during severe inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

Fanconi-Bickel syndrome in a 3-year-old Indian boy with a novel mutation in the GLUT2 gene

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

Effect of a high-fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2 inhibitor, in healthy subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

Glomerular hyperfiltration in type 1 diabetes mellitus results from primary changes in proximal tubular sodium handling without changes in volume expansion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.243

31 March 2020

Learning from glycosuria

1 reference

12 December 2020

Effect of phlorizin on SGLT2 expression in the kidney of diabetic rats.

1 reference

12 December 2020

Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption

1 reference

12 December 2020

Effect of insulin on uric acid excretion in humans.

1 reference

12 December 2020

Complete absence of tubular glucose reabsorption: a new type of renal glucosuria (type 0)

1 reference

12 December 2020